Results 151 to 160 of about 73,900 (261)

Advancements in Enzymatic Biofuel Cells for Wearable Electrochemical Biosensors: Powering Point‐of‐Care Health Monitoring

open access: yesAdvanced Sensor Research, Volume 5, Issue 8, August 2026.
Advances in enzymatic biofuel cells are highlighted through innovative electrode architectures, enzyme immobilization strategies, and hybrid integration with triboelectric, piezoelectric, and thermoelectric energy harvesters. These emerging approaches improve power output, operational stability, and biocompatibility, advancing self‐powered wearable and
Rashid Khan   +3 more
wiley   +1 more source

m.10010T>C Mitochondrial Disease: A Case Report With Hypoparathyroidism and Review of the Literature

open access: yesAmerican Journal of Medical Genetics Part A, Volume 200, Issue 8, Page 1856-1861, August 2026.
ABSTRACT Mitochondria are essential intracellular organelles that play a critical role in cellular metabolism, including the regulation of intracellular calcium signaling. Advances in genomic sequencing have facilitated the identification of rare pathogenic mitochondrial DNA (mtDNA) genetic variants in patients with unexplained endocrine disorders.
Jacob Mohr   +5 more
wiley   +1 more source

Tacrolimus‐Associated Calcium Pyrophosphate Crystal Arthritis in a Kidney Transplant Recipient: An Underrecognized Condition

open access: yesClinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Providers who care for renal transplant recipients should be aware of the possibility of tacrolimus‐associated CPPD in patients who present with arthritis. In the case presented, a delayed diagnosis led to the progression of symptoms and avoidable disability, underscoring the need for greater clinical awareness of this condition within the ...
Matthew Wyke   +5 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 334-344, August 2026.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy